DNAH7 mutations benefit colorectal cancer patients receiving immune checkpoint inhibitors

BACKGROUND: Colorectal cancer (CRC) is a malignant tumor associated with a high mortality rate. While the advent of immune checkpoint inhibitors (ICIs) has been a gamechanger, only a small percentage of CRC patients benefit from ICIs. The pathological mechanism of CRC is not well understood, but som...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenjuan, Shen, Zhengjie, Yang, Ti, Wu, Mianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843387/
https://www.ncbi.nlm.nih.gov/pubmed/36660654
http://dx.doi.org/10.21037/atm-22-6166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843387/
https://www.ncbi.nlm.nih.gov/pubmed/36660654
http://dx.doi.org/10.21037/atm-22-6166

Ejemplares similares